Abstract:The designed and synthesized multifunctional properties of bis-hydrazono[1,3,4]thiadiazoles became important for developing an efficient medication for Alzheimer's disease. Thiadiazoles were characterized and studied towards this target as an acetylcholinesterase inhibitor (ChEIs). In this study, one-pot synthetic strategy was applied for the synthesis of bis-hydrazono[1,3,4]thiadiazole series from 2,2′-(1,2-diphenylethane-1,2-diylidene)bis(hydrazine-1-carbodithioic acid) and hydrazonoyl chlorides. The greener pastures, in silico, an environmentally-friendly and free computer-aided method, bioactivity studies of the bis-hydrazono[1,3,4]thiadiazoles 4a-h exhibited various possible interesting inhibitory activities against AChE showing similar behaviour to the approved drugs, Donepezil, Galantamine and Rivastigmine. For a fair comparison, the superpositions of 4a-h, and Donepezil, Galantamine and Rivastigmine docked together into the functional domain (binding pocket) of 1EVE to reveal interesting different molecular laydowns of the compounds. On the other side, the display of the molecules before and after docking was discussed. The binding affinity slightly differs between Donepezil, Galantamine, Rivastigmine, and the ligands 4a-h. The range of the recorded binding affinity for 4a-h is from (−9.4 to −8.4 kcal/mol −1 ) , whereas the binding affinity for Donepezil, Galantamine and Rivastigmine is (−11.1, −9.8 and −8.0 kcal/mol −1 respectively), which is higher than all the prepared ligands. Furthermore, the binding amino acids also varied among the studied compounds in this study. Phe290, Phe330, Phe331, Trp279, Tyr70, Tyr121 and Tyr334 are the common amino acids binding with the FDA-approved AChE inhibitors for treating AD, Donepezil, Galantamine and Rivastigmine and ligands. Notably, the number of hydrophobic and hydrogen interactions studied between the ligands 4a-h and the Donepezil, Galantamine and Rivastigmine drugs were compared as a preliminary indicator towards a successful inhibitor. The comparative study in this research work aims to rank our compounds with respect to the approved medications. This is a friendly environmental preliminary helpful indication before leaping into time and energy-consuming experimental work. Organ toxicological endpoints and toxicity-predicted activity were obtained using the ProTox-II web server for both the approved medication and ligands. Later, in-vitro acetylcholinesterase inhibition assays were conducted to assess the efficacy of bis-hydrazono[1,3,4]thiadiazoles 4a-h as inhibitors of acetylcholinesterase (AChE) in comparison to Donepezil. Results indicated promising inhibition activities for example 4 h, 4 g and 4d to the testing drug Donepezil for breaking down the neurotransmitter acetylcholine. Graphical abstract Download : Download high-res image (210KB) Download : Download full-size image

Benzyloxychalcone Hybrids as Prospective Acetylcholinesterase Inhibitors against Alzheimer's Disease: Rational Design, Synthesis, In Silico ADMET Prediction, QSAR, Molecular Docking, DFT, and Molecular Dynamic Simulation Studies

Novel chalcone derivatives of ursolic acid as acetylcholinesterase inhibitors: Synthesis, characterization, biological activity, ADME prediction, molecular docking and molecular dynamics studies

Design, synthesis, anti-acetylcholinesterase evaluation and molecular modelling studies of novel coumarin-chalcone hybrids

Design, Synthesis, In Vitro Biological Evaluation and In Silico Molecular Docking Study of Benzimidazole-Based Oxazole Analogues: A Promising Acetylcholinesterase and Butyrylcholinesterase Inhibitors

Synthesis, in Vitro Cholinesterase Inhibition, Molecular Docking, DFT, and ADME Studies of Novel 1,3,4‐oxadiazole‐2‐thiol Derivatives

Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti‐Alzheimer's agents

Synthesis of Flavonoid/Sulfonamide Hybrid Molecules as Potential Inhibitors of Cholinesterases: In Vitro, Molecular Docking, Molecular Dynamic and DFT Studies

Insight from molecular modeling and ADMET analysis: Design, synthesis and in vitro acetylcholinesterase and butyrylcholinesterase assessment of thiazolidinone containing benzoxazole hybrids derivatives

Computational Prediction of 3,5-Diaryl-1H-Pyrazole and spiropyrazolines derivatives as potential acetylcholinesterase inhibitors for alzheimer disease treatment by 3D-QSAR, molecular docking, molecular dynamics simulation, and ADME-Tox

Novel Potent and Selective Acetylcholinesterase Inhibitors As Potential Drugs for the Treatment of Alzheimer'S Disease: Synthesis, Pharmacological Evaluation, and Molecular Modeling of Amino-Alkyl-Substituted Fluoro-Chalcones Derivatives

ADME properties, bioactivity and molecular docking studies of 4-amino-chalcone derivatives: new analogues for the treatment of Alzheimer, glaucoma and epileptic diseases

Synthesis, In Vitro Biological Evaluation and Molecular Modeling of Benzimidazole-Based Pyrrole/Piperidine Hybrids Derivatives as Potential Anti-Alzheimer Agents

Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Chalcone-Rivastigmine Hybrids As Cholinesterase Inhibitors

Multi-combined QSAR, molecular docking, molecular dynamics simulation, and ADMET of Flavonoid derivatives as potent cholinesterase inhibitors

Design, synthesis and molecular docking and ADME studies of novel hydrazone derivatives for AChE inhibitory, BBB permeability and antioxidant effects

Synthesis, biological and computational evaluation of benzoxazole hybrid analogs as potential anti-Alzheimer's agents

In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease

N‐methylpiperazinyl and piperdinylalkyl‐O‐chalcone derivatives as potential polyfunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation

Newly synthesized Bis-Hydrazono[1,3,4] thiadiazoles as Anti-Alzheimer's Agents: Greener past and In-Vitro acetylcholinesterase inhibition assay investigations

Design, synthesis and evaluation of imidazo[1,2-a]pyrazin-8(7H)-one derivatives as acetylcholinesterase inhibitors and antioxidants

Identification of AChE targeted therapeutic compounds for Alzheimer's disease: an in-silico study with DFT integration